{"title":"辉瑞向默克支付8.5亿美元，在免疫肿瘤学领域展开竞争","authors":"Heather Cartwright","doi":"10.3833/PDR.V2014I12.2082","DOIUrl":null,"url":null,"abstract":"In a deal that suggests that it may no longer be interested in acquiring AstraZeneca, Pfizer has agreed to pay Merck KGaA US$850 M upfront in order to co-develop and co-commercialise the German company’s anti-PD-L1 (programmed deathligand-1) antibody MSB0010718C, which is being evaluated in a Phase II trial in patients with Merkel cell carcinoma. The deal, which provides a much-needed boost to Merck’s pipeline prospects, will help advance Pfizer’s position in the highly competitive immuno-oncology field. It also allows Merck to enter the US oncology market by giving it co-promotion rights to Pfizer’s Xalkori® (crizotinib).","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"73 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2014-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pfizer Pays Merck KGaA US$850 M Upfront to Compete in Immuno-Oncology\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2014I12.2082\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In a deal that suggests that it may no longer be interested in acquiring AstraZeneca, Pfizer has agreed to pay Merck KGaA US$850 M upfront in order to co-develop and co-commercialise the German company’s anti-PD-L1 (programmed deathligand-1) antibody MSB0010718C, which is being evaluated in a Phase II trial in patients with Merkel cell carcinoma. The deal, which provides a much-needed boost to Merck’s pipeline prospects, will help advance Pfizer’s position in the highly competitive immuno-oncology field. It also allows Merck to enter the US oncology market by giving it co-promotion rights to Pfizer’s Xalkori® (crizotinib).\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"73 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2014I12.2082\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2014I12.2082","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Pfizer Pays Merck KGaA US$850 M Upfront to Compete in Immuno-Oncology
In a deal that suggests that it may no longer be interested in acquiring AstraZeneca, Pfizer has agreed to pay Merck KGaA US$850 M upfront in order to co-develop and co-commercialise the German company’s anti-PD-L1 (programmed deathligand-1) antibody MSB0010718C, which is being evaluated in a Phase II trial in patients with Merkel cell carcinoma. The deal, which provides a much-needed boost to Merck’s pipeline prospects, will help advance Pfizer’s position in the highly competitive immuno-oncology field. It also allows Merck to enter the US oncology market by giving it co-promotion rights to Pfizer’s Xalkori® (crizotinib).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
